/

Cerus Corporation

CERS US

CERS USCerus Corporation

United States Composite

1.64

USD

-0.04

(-2.38%)

-0.21EPS Dil.

-7.89P/E

297.25MMarket Cap

Next Earnings

May 2

Held by Insiders

3.76%

Held by Institutions

74.96%

Short % of Float

2.48%

YTD Yield

-30.88%

3Y Yield

-69.58%

5Y Yield

-67.30%

Capital Structure

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

ST Debt

LT Borrowings

LT Finance Leases

Preferred Equity and Hybrid Capital

- -

Shares Outstanding

181

Market Capitalization

445

293

391

Working Capital

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

Total Current Assets

151

144

Cash, Cash Equivalents & STI

Accounts Receivable, Net

Inventories

Total Current Liabilities

Payables & Accruals

ST Debt

Deferred Revenue

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

15.88%

21.59%

-3.70%

Net Income, GAAP

-0.13%

7.48%

13.95%

Free Cash Flow

-16.39%

-24.44%

-71.43%

Total Cash Common Dividend

- -

Total Equity

15.94%

-2.15%

-23.19%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

2021

131

2022

162

2023

156

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

2021

-0.10

-0.09

-0.07

-0.05

-0.32

2022

-0.07

-0.05

-0.08

-0.24

2023

-0.09

-0.07

-0.04

-0.01

-0.21

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

2021

- -

2022

- -

2023

- -

Company Description

CEO: Mr. William M. Greenman
Full Time Employees: 625
Sector: Healthcare
Industry: Medical Devices
Address: 1220 Concord Avenue Concord CA United States 94520
IPO Date: Jan 31, 1997
CIK: 0001020214
Website: www.cerus.com
Business: Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.

Company News

Tipranks
6 days ago
Cerus Corporation: Strong Buy Rating Amidst Growth and Path to Profitability
Yahoo
23 days ago
Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets – Doubling Previous Shelf Life
Yahoo
a month ago
Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients
Tipranks
a month ago
Cerus’s Strong Q4 Performance and Positive 2024 Outlook Prompt ‘Buy’ Rating
Yahoo
a month ago
Insider Sell: President and CEO William Greenman Sells 125,926 Shares of Cerus Corp (CERS)
Yahoo
a month ago
Insider Sell: COO Vivek Jayaraman Sells 53,041 Shares of Cerus Corp (CERS)
Tipranks
a month ago
Analysts Offer Insights on Healthcare Companies: iCAD (ICAD), Mustang Bio (MBIO) and Cerus (CERS)
Yahoo
a month ago
Earnings Release: Here's Why Analysts Cut Their Cerus Corporation (NASDAQ:CERS) Price Target To US$4.13
Yahoo
a month ago
Cerus Corp (CERS) Posts Narrowed Q4 Net Loss and Achieves Adjusted EBITDA Breakeven
Yahoo
a month ago
Cerus Corporation (NASDAQ:CERS) Q4 2023 Earnings Call Transcript
Yahoo
a month ago
Cerus Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
Tipranks
a month ago
Cerus Corporation’s New Share Price & Shareholder Rights Risk – A Cause for Worry?
Tipranks
a month ago
Stifel Nicolaus Keeps Their Buy Rating on Cerus (CERS)
Yahoo
a month ago
Q4 2023 Cerus Corp Earnings Call
Yahoo
a month ago
Cerus Corporation Announces Fourth Quarter and Full-Year 2023 Financial Results

Company Description

CEO: Mr. William M. Greenman
Full Time Employees: 625
Sector: Healthcare
Industry: Medical Devices
Address: 1220 Concord Avenue Concord CA United States 94520
IPO Date: Jan 31, 1997
CIK: 0001020214
Website: www.cerus.com
Business: Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.

Company News

Tipranks
6 days ago
Cerus Corporation: Strong Buy Rating Amidst Growth and Path to Profitability
Yahoo
23 days ago
Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets – Doubling Previous Shelf Life
Yahoo
a month ago
Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients
Tipranks
a month ago
Cerus’s Strong Q4 Performance and Positive 2024 Outlook Prompt ‘Buy’ Rating
Yahoo
a month ago
Insider Sell: President and CEO William Greenman Sells 125,926 Shares of Cerus Corp (CERS)
Yahoo
a month ago
Insider Sell: COO Vivek Jayaraman Sells 53,041 Shares of Cerus Corp (CERS)
Tipranks
a month ago
Analysts Offer Insights on Healthcare Companies: iCAD (ICAD), Mustang Bio (MBIO) and Cerus (CERS)
Yahoo
a month ago
Earnings Release: Here's Why Analysts Cut Their Cerus Corporation (NASDAQ:CERS) Price Target To US$4.13
Yahoo
a month ago
Cerus Corp (CERS) Posts Narrowed Q4 Net Loss and Achieves Adjusted EBITDA Breakeven
Yahoo
a month ago
Cerus Corporation (NASDAQ:CERS) Q4 2023 Earnings Call Transcript
Yahoo
a month ago
Cerus Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
Tipranks
a month ago
Cerus Corporation’s New Share Price & Shareholder Rights Risk – A Cause for Worry?
Tipranks
a month ago
Stifel Nicolaus Keeps Their Buy Rating on Cerus (CERS)
Yahoo
a month ago
Q4 2023 Cerus Corp Earnings Call
Yahoo
a month ago
Cerus Corporation Announces Fourth Quarter and Full-Year 2023 Financial Results